Survival in patients aged 50 to 70 and those aged 65 to 70
. | MEL100 . | . | . | MP . | . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ages and survival status . | No. . | No. failed (%) . | Median (mos) . | No. . | No. failed (%) . | Median (mos.) . | HR* . | CI . | P . | ||||
| 50 to 70 years | |||||||||||||
| EFS | 95 | 58 (60) | 28.0 | 99 | 81 (82) | 15.6 | 0.48 | 0.34-0.66 | < .0001 | ||||
| OS | 95 | 19 (20) | 58+ | 99 | 34 (34) | 42.5 | 0.40 | 0.24-0.67 | < .001 | ||||
| 65 to 70 years | |||||||||||||
| EFS | 44 | 29 (66) | 28.0 | 36 | 29 (80.6) | 16.4 | 0.55 | 0.33-0.92 | .023 | ||||
| OS | 44 | 10 (22.7) | 58.0 | 36 | 14 (38.8) | 37.2 | 0.46 | 0.22-0.98 | .04 | ||||
. | MEL100 . | . | . | MP . | . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ages and survival status . | No. . | No. failed (%) . | Median (mos) . | No. . | No. failed (%) . | Median (mos.) . | HR* . | CI . | P . | ||||
| 50 to 70 years | |||||||||||||
| EFS | 95 | 58 (60) | 28.0 | 99 | 81 (82) | 15.6 | 0.48 | 0.34-0.66 | < .0001 | ||||
| OS | 95 | 19 (20) | 58+ | 99 | 34 (34) | 42.5 | 0.40 | 0.24-0.67 | < .001 | ||||
| 65 to 70 years | |||||||||||||
| EFS | 44 | 29 (66) | 28.0 | 36 | 29 (80.6) | 16.4 | 0.55 | 0.33-0.92 | .023 | ||||
| OS | 44 | 10 (22.7) | 58.0 | 36 | 14 (38.8) | 37.2 | 0.46 | 0.22-0.98 | .04 | ||||
Adjusted for age, gender, isotype, stage, and β2-microglobulin with a Cox proportional hazard model.